ECSP17006751A - Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo - Google Patents

Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo

Info

Publication number
ECSP17006751A
ECSP17006751A ECIEPI20176751A ECPI201706751A ECSP17006751A EC SP17006751 A ECSP17006751 A EC SP17006751A EC IEPI20176751 A ECIEPI20176751 A EC IEPI20176751A EC PI201706751 A ECPI201706751 A EC PI201706751A EC SP17006751 A ECSP17006751 A EC SP17006751A
Authority
EC
Ecuador
Prior art keywords
inhibitors
compounds useful
activating enzyme
heteroaryl compounds
sumo activating
Prior art date
Application number
ECIEPI20176751A
Other languages
English (en)
Spanish (es)
Inventor
Steven Langston
Hirotake Mizutani
Koji Ono
Matthew O Duffey
Scott Freeze
He Xu
Charles Mcintyre
Zhigen Hu
Dylan England
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55019950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17006751(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of ECSP17006751A publication Critical patent/ECSP17006751A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes
    • C07F9/5352—Phosphoranes containing the structure P=C-
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ECIEPI20176751A 2014-07-01 2017-02-01 Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo ECSP17006751A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462019756P 2014-07-01 2014-07-01
US201562185678P 2015-06-28 2015-06-28

Publications (1)

Publication Number Publication Date
ECSP17006751A true ECSP17006751A (es) 2017-02-24

Family

ID=55019950

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20176751A ECSP17006751A (es) 2014-07-01 2017-02-01 Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo

Country Status (39)

Country Link
US (6) US9683003B2 (enExample)
EP (3) EP3164130B1 (enExample)
JP (4) JP6603712B2 (enExample)
KR (1) KR102491125B1 (enExample)
CN (1) CN106999479B (enExample)
AU (1) AU2015284135B2 (enExample)
BR (1) BR112016030787B1 (enExample)
CA (1) CA2953132C (enExample)
CL (1) CL2016003398A1 (enExample)
CR (1) CR20170021A (enExample)
CY (1) CY1122808T1 (enExample)
DK (1) DK3164130T3 (enExample)
DO (1) DOP2016000339A (enExample)
EA (1) EA034119B1 (enExample)
EC (1) ECSP17006751A (enExample)
ES (1) ES2754359T3 (enExample)
GE (2) GEAP201914395A (enExample)
HR (1) HRP20191979T1 (enExample)
HU (1) HUE045748T2 (enExample)
IL (1) IL249820B (enExample)
LT (1) LT3164130T (enExample)
ME (1) ME03574B (enExample)
MX (1) MX376054B (enExample)
MY (1) MY183649A (enExample)
NZ (1) NZ728162A (enExample)
PE (1) PE20170520A1 (enExample)
PH (1) PH12016502595B1 (enExample)
PL (1) PL3164130T3 (enExample)
PT (1) PT3164130T (enExample)
RS (1) RS59474B1 (enExample)
SG (1) SG11201610476VA (enExample)
SI (1) SI3164130T1 (enExample)
SM (1) SMT201900600T1 (enExample)
TN (1) TN2016000581A1 (enExample)
TW (1) TWI680970B (enExample)
UA (1) UA122963C2 (enExample)
UY (1) UY36198A (enExample)
WO (1) WO2016004136A1 (enExample)
ZA (1) ZA201700386B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2864672C (en) 2012-02-17 2018-01-09 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
WO2014022744A1 (en) 2012-08-03 2014-02-06 Millennium Pharmaceuticals, Inc. INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6
JP6603712B2 (ja) 2014-07-01 2019-11-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｓｕｍｏ活性化酵素の阻害薬として有用なヘテロアリール化合物
US10465447B2 (en) 2015-03-12 2019-11-05 Baker Hughes, A Ge Company, Llc Cutting elements configured to mitigate diamond table failure, earth-boring tools including such cutting elements, and related methods
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
MA46341A (fr) 2016-10-03 2019-08-07 Janssen Pharmaceutica Nv Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
KR102573149B1 (ko) 2017-02-27 2023-08-30 얀센 파마슈티카 엔.브이. Prmt5 저해제를 이용한 치료에 대하여 반응성인 암환자의 확인에 있어서의 바이오마커의 용도
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
US10400517B2 (en) 2017-05-02 2019-09-03 Baker Hughes, A Ge Company, Llc Cutting elements configured to reduce impact damage and related tools and methods
US11124519B2 (en) 2017-09-21 2021-09-21 Millennium Pharmaceuticals, Inc. Cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof
ES2978117T3 (es) 2017-12-08 2024-09-05 Janssen Pharmaceutica Nv Nuevos análogos espirobicíclicos
US20210015915A1 (en) 2018-03-23 2021-01-21 Takeda Pharmaceutical Company Limited Sting modulator compounds with sulfamate linkages, and methods of making and using
CN119751456A (zh) 2018-04-16 2025-04-04 C4医药公司 螺环化合物
KR20210031679A (ko) * 2018-07-09 2021-03-22 밀레니엄 파머슈티컬스 인코퍼레이티드 수모-활성화 효소 저해제 및 항-cd20 항체의 투여
US10570668B2 (en) 2018-07-27 2020-02-25 Baker Hughes, A Ge Company, Llc Cutting elements configured to reduce impact damage and mitigate polycrystalline, superabrasive material failure earth-boring tools including such cutting elements, and related methods
CN109354569A (zh) * 2018-11-27 2019-02-19 常州大学 一种1,3-二溴-4-氟苯的制备方法
EP3930720A4 (en) * 2019-02-26 2022-12-28 Millennium Pharmaceuticals, Inc. COMPOUNDS USEFUL AS ADJUVANTS
JP7539896B2 (ja) * 2019-02-27 2024-08-26 武田薬品工業株式会社 Ｓｕｍｏ活性化酵素阻害剤及びチェックポイント阻害剤の投与
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
EP3782702A1 (en) * 2019-08-21 2021-02-24 AC BioScience SA Compounds and use thereof for the treatment of infectious diseases and cancer
CN112402608B (zh) * 2020-11-30 2021-09-07 深圳先进技术研究院 5-烷氧基吲哚-3-乙烯基喹啉盐作为靶向可迁移光敏剂的应用
WO2021203001A1 (en) * 2020-04-03 2021-10-07 Millennium Pharmaceuticals, Inc. Method of treating patients infected with a viral infection with an inhibitor of small ubiquitin like modifier activating enzyme
TW202207935A (zh) * 2020-05-15 2022-03-01 美商千禧製藥公司 Ｓｕｍｏ活化酶抑制劑及抗ｃｄ３８抗體之投與
CN116917594A (zh) 2021-02-05 2023-10-20 贝克休斯油田作业有限责任公司 钻地工具的切割元件以及制造钻地工具的方法
CN113173852B (zh) * 2021-04-26 2022-07-12 深圳市华先医药科技有限公司 二氟丙二酸酯类化合物的制备方法
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
US11920409B2 (en) 2022-07-05 2024-03-05 Baker Hughes Oilfield Operations Llc Cutting elements, earth-boring tools including the cutting elements, and methods of forming the earth-boring tools
CN119585283A (zh) 2022-09-30 2025-03-07 微境生物医药科技(上海)有限公司 作为sumo活化酶抑制剂的化合物
CN120112536A (zh) * 2022-11-11 2025-06-06 微境生物医药科技(上海)有限公司 作为sumo活化酶抑制剂的化合物
WO2024110863A1 (en) 2022-11-22 2024-05-30 Takeda Pharmaceutical Company Limited Process and intermediates for preparing ((1r,2s,4r)-4-((5-(4-((r)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-methylthiophene-2-carbonyl)pyrimidin-4-yl)amino)-2-hydroxycyclopentyl)methyl sulfamate
CN117209449B (zh) * 2023-09-14 2025-11-28 上海毕得医药科技股份有限公司 一种2-(三氟甲基)噻唑类化合物的合成方法
NL2035852B1 (en) 2023-09-21 2025-03-28 Academisch Ziekenhuis Leiden Enhancement of t cell mediated therapies
CN119371416B (zh) * 2024-12-23 2025-05-30 上海达歌生物医药科技有限公司 一种通过氧杂环丁烷开环以构建4-取代异香豆素及其类似物的合成方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
WO1997005132A1 (en) 1995-07-28 1997-02-13 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
AU2003213628A1 (en) 2002-02-28 2003-09-16 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
AU2003226188A1 (en) * 2002-04-10 2003-10-27 Ortho-Mcneil Pharmaceutical, Inc. Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
US7527966B2 (en) 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
US7291603B2 (en) 2002-07-24 2007-11-06 Ptc Therapeutics, Inc. Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
AU2003261237A1 (en) 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
ATE362474T1 (de) 2002-09-04 2007-06-15 Schering Corp Pyrazolo(1,5-a)pyrimidine als hemmstoffe cyclin- abhängiger kinasen
ATE364608T1 (de) 2002-09-04 2007-07-15 Schering Corp Pyrazolopyrimidine als hemmstoffe cyclin- abhängiger kinasen
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
AU2003291024A1 (en) 2002-11-13 2004-06-03 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
EP1608652A1 (en) 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
EP1690863A1 (en) 2003-11-26 2006-08-16 Dainippon Sumitomo Pharma Co., Ltd. Novel condensed imidazole derivative
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
ES2390803T3 (es) 2005-02-04 2012-11-16 Millennium Pharmaceuticals, Inc. Inhibidores de las enzimas activadoras E1
CN101321759A (zh) 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
EA024006B1 (ru) 2006-02-02 2016-08-31 Миллениум Фармасьютикалз, Инк. Ингибиторы е1 активирующих ферментов
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
DE602007009998D1 (de) * 2006-08-08 2010-12-02 Millennium Pharm Inc Heteroarylverbindungen als hemmer der e1-aktivierenden enzyme
TWI574941B (zh) 2007-06-12 2017-03-21 Achaogen Inc 抗菌劑
ES2655028T3 (es) 2007-08-02 2018-02-16 Millennium Pharmaceuticals, Inc. Proceso para la síntesis de inhibidores de enzima de activación de E1
US9216983B2 (en) 2007-12-21 2015-12-22 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
TW201019939A (en) 2008-08-20 2010-06-01 Schering Corp Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TWI409265B (zh) 2008-08-20 2013-09-21 Merck Sharp & Dohme 經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途
WO2010022128A1 (en) 2008-08-20 2010-02-25 Schering Corporation Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734487A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009298802A1 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
SG10201402148SA (en) 2009-05-14 2014-07-30 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
EA201290062A1 (ru) 2009-08-17 2013-09-30 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений
WO2011100131A2 (en) 2010-01-28 2011-08-18 Alnylam Pharmacuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2011109059A1 (en) 2010-03-01 2011-09-09 Gtx, Inc. Compounds for treatment of cancer
SG186850A1 (en) 2010-07-29 2013-02-28 Rigel Pharmaceuticals Inc Ampk-activating heterocyclic compounds and methods for using the same
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
BR112014004239A2 (pt) 2011-08-24 2017-03-21 Millennium Pharm Inc inibidores de enzima ativadora de nedd8
WO2013066729A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
CA2864672C (en) 2012-02-17 2018-01-09 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
JP6378759B2 (ja) * 2013-07-02 2018-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｓｕｍｏ活性化酵素阻害剤として有用なヘテロアリール化合物
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
EP3060550B1 (en) 2013-10-21 2019-05-15 Merck Patent GmbH Heteroaryl compounds as btk inhibitors and uses thereof
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof
JP6603712B2 (ja) 2014-07-01 2019-11-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｓｕｍｏ活性化酵素の阻害薬として有用なヘテロアリール化合物

Also Published As

Publication number Publication date
US10780090B2 (en) 2020-09-22
UA122963C2 (uk) 2021-01-27
ME03574B (me) 2020-07-20
TN2016000581A1 (en) 2018-04-04
JP2024012558A (ja) 2024-01-30
AU2015284135A1 (en) 2017-02-09
PH12016502595B1 (en) 2021-09-10
CN106999479B (zh) 2021-07-16
GEAP201914395A (en) 2019-06-10
MY183649A (en) 2021-03-05
PT3164130T (pt) 2019-11-18
LT3164130T (lt) 2019-11-25
SG11201610476VA (en) 2017-01-27
CN106999479A (zh) 2017-08-01
JP2021178869A (ja) 2021-11-18
US20200085821A1 (en) 2020-03-19
US20230293522A1 (en) 2023-09-21
EP3164130A1 (en) 2017-05-10
BR112016030787A2 (pt) 2017-08-22
US9683003B2 (en) 2017-06-20
PL3164130T3 (pl) 2020-02-28
AU2015284135B2 (en) 2019-11-28
EP3517112B1 (en) 2021-04-07
EP3517112A1 (en) 2019-07-31
JP2017524734A (ja) 2017-08-31
US20170216290A1 (en) 2017-08-03
WO2016004136A1 (en) 2016-01-07
TWI680970B (zh) 2020-01-01
EA201790108A1 (ru) 2017-07-31
CA2953132A1 (en) 2016-01-07
RS59474B1 (sr) 2019-12-31
PH12016502595A1 (en) 2017-04-24
US20160009744A1 (en) 2016-01-14
TW201613903A (en) 2016-04-16
ES2754359T3 (es) 2020-04-17
EP3901159A1 (en) 2021-10-27
MX376054B (es) 2025-03-07
US10335410B2 (en) 2019-07-02
HUE045748T2 (hu) 2020-01-28
DOP2016000339A (es) 2017-03-15
DK3164130T3 (da) 2019-10-28
JP2020023538A (ja) 2020-02-13
KR20170032334A (ko) 2017-03-22
EA034119B1 (ru) 2019-12-30
CA2953132C (en) 2023-04-11
UY36198A (es) 2016-01-29
CY1122808T1 (el) 2021-05-05
KR102491125B1 (ko) 2023-01-20
BR112016030787B1 (pt) 2022-12-20
EP3164130A4 (en) 2018-02-14
ZA201700386B (en) 2018-11-28
HRP20191979T1 (hr) 2020-02-07
BR112016030787A8 (pt) 2021-07-20
SI3164130T1 (sl) 2019-12-31
CL2016003398A1 (es) 2017-12-29
IL249820B (en) 2019-09-26
US20220331316A1 (en) 2022-10-20
SMT201900600T1 (it) 2020-01-14
PE20170520A1 (es) 2017-05-24
CR20170021A (es) 2017-04-04
IL249820A0 (en) 2017-02-28
NZ728162A (en) 2023-06-30
US20170002032A9 (en) 2017-01-05
EP3164130B1 (en) 2019-08-07
MX2016016993A (es) 2017-02-27
US9962386B2 (en) 2018-05-08
JP6603712B2 (ja) 2019-11-06
US20180311239A1 (en) 2018-11-01
GEP20197047B (en) 2019-12-10

Similar Documents

Publication Publication Date Title
ECSP17006751A (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo
ECSP17039127A (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática
ECSP17029371A (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
ECSP18090743A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
GEAP201814288A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
PT3105226T (pt) Ciclopropilaminas como inibidores de lsd1
EP3102576B8 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
EP3016934A4 (en) HETEROARYL COMPOUNDS FOR USE AS INHIBITORS OF SAE ENZYME
GEAP201814347A (en) Substituted dihydroisoquinoline compounds
TWD187032S (zh) 工業機器人
ECSP15035278A (es) Compuestos de azabencimidazol
EP3183255C0 (en) SPIROPYRROLIDINES USEFUL AS MDM2 INHIBITORS
TWD177712S (zh) 置物架
FR3024465B1 (fr) Caracterisation de micro-organismes par maldi-tof
TWD169384S (zh) 包裝盒
PT3552017T (pt) Compostos úteis como inibidores de ripk1
ECSP17014972A (es) Compuestos de azetidiniloxifenilpirrolidina
TWD171710S (zh) 端子
ECSP17050310A (es) Ciclopropabenzofuranil-piridopirazindionas novedosas
AU2015311730A8 (en) CaMKII inhibitors and uses thereof
CL2016001959A1 (es) Hexahidrofuropirroles como inhibidores de pde1
AU2016205137B2 (en) Furoquinolinediones as inhibitors of TDP2
TWD171709S (zh) 端子
ECSP17015682A (es) Inhibidores cristalinos de bace
GB201312311D0 (en) Uses of enzyme inhibitors